Bioregenx, Inc.

BRGX OTC SEC CIK 1593184
Follow Bioregenx Weekly email: filings, results, news

Financials

Reported figures only · latest: Q1 2026 USD · US GAAP
Revenue, last quarter $426.2K −17.3% vs same quarter last year
Net income −$26.4K +90.1% vs same quarter last year
EPS, diluted $0.00
Operating cash flow $26.6K −29.4% vs same quarter last year
Revenue by quarter
$734K
$596K
$460.5K
$515.1K
$446K
$507.8K
$385.6K
$426.2K
Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
  • Revenue
  • Net income
−$30M−$20M−$10M$0$10MFY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$1.9M−$1.5M
FY24$2.3M−$23.1M
FY23$3.4M−$3.6M
FY22$42.2K−$78.3K
FY21$198.6K−$96.9K
FY20--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−1000%−500%0%500%FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2581.1%−67.1%−83.2%
FY2470.9%−972.7%−985.2%
FY2367.8%−99.9%−105.5%
FY22100%−185.7%−185.7%
FY2199.7%−83.1%−48.8%
FY20---
Free cash flowOperating cash flow minus capital expenditure
−$2M−$1.5M−$1M−$500K$0$500KFY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25$29.9K
FY24−$513.5K
FY23−$1.5M
FY22-
FY21-
FY20-
Net margin vs the sectorMedian of Technology companies filing with the SEC
  • Bioregenx
  • Technology median
−1000%−750%−500%−250%0%FY20FY21FY22FY23FY24FY25
Show the numbers
YearBioregenxTechnology median
FY25−83.2%0%
FY24−985.2%−1.8%
FY23−105.5%−5.8%
FY22−185.7%−5.1%
FY21−48.8%−4.3%
FY20-−7.9%

News

No stories filed under Bioregenx yet - coverage appears here as the news feed clusters it.